SEARCH

SEARCH BY CITATION

References

  • Alexander RW (1995). Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 25: 155161.
  • Alexander RW (2002). Oxidised LDL autoantibodies, endothelial dysfunction and transplant-associated atheroscelerosis. Arterioscler Thromb Vasc Biol 22: 19501951.
  • Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd Edition (2008 Revision). Br J Pharmacol 153: S1S209.
  • Badimon L, Vilahur G, Sanchez S, Duran X (2001). Atherosclerosis plaque formation and thrombogenesis: formation, risk factors and therapeutic approaches. Eur Heart J 3: I16I22.
  • Bajaj M, Medina-Navarro R, Suraamornkul S, Meyer C, DeFronzo RA, Mandarino LJ (2007). Paradoxical changes in muscle gene expression in insulin-resistant subjects after sustained reduction in plasma free fatty acid concentration. Diabetes 56: 743752.
  • Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH (2008). Comparison of the saftey and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST-1 study). Am J Cardiol 101: 14281436.
  • Basu TK, Makhani N, Sedgwick G (2002). Niacin (nicotinic acid) in non-physiological doses cause hyperhomocysteineaemia in Sprague-Dawley rats. Br J Nutr 87: 115119.
  • Bax JJ, Veening MA, Visser FC, Heine RJ, Cornel JH, Visser CA (1997). Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging: a comparative study using different protocols. Eur J Nucl Med 24: 3541.
  • Bellows CF, Alder A, Wludyka P, Jaffe BM (2005). Modulation of macrophage nitric oxide production by prostaglandin D2. J Surg Res 132: 9297.
  • Benyo Z, Gille A, Kero J, Csiky M, Suchankova MC, Nusing RM et al. (2005). GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 115: 36343640.
  • Benyo Z, Gille A, Bennett CL, Clausen BE, Offermanns S (2006). Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol Pharmacol 70: 18441849.
  • Blachere J-C, Perusse F, Bukowiecki LJ (2001). Lowering plasma free fatty acids with acipimox mimics the antidiabetic effects of the β3-adrenergic agonist CL-16243 in obese Zucker diabetic fatty rats. Metabolism 50: 945951.
  • Bodor ET, Offermanns S (2008). Nicotinic acid: an old drug with a promising future. Br J Pharmacol 153: S68S75.
  • Boudjeltia K, Legssyer I, Van Antwerpen P, Kisoka R, Babar S, Moguilevsky N et al. (2006). Triggering of inflammatory response by myeloperoxidase-oxidized LDL. Biochem Cell Biol 84: 805812.
  • Brun RP, Spiegelman BM (1997). PPARgamma and the molecular control of adipogenesis. J Endocrinol 155: 217218.
  • Cayen MN, Kallai-Sanfacon MA, Dubuc J, Greselin E, Dvornik D (1982). Evaluation of the lipid-lowering activity of AY-25,712 in rats. Atherosclerosis 45: 267279.
  • Cayen MN, Gonzalez R, Ferdinandi ES, Greselin E, Hicks DR, Kraml M et al. (1986). The metabolic disposition of acifran, a new antihyperlipidaemic agent, in rats and dogs. Xenobiotica 16: 251263.
  • Cayen MN, Ferdinandi ES, Hicks DR, Gonzalez R, Cosyns L, Dubuc J et al. (1990). Pharmacokinetics and disposition of the lipid-lowering drug acifran in normal subjects and in patients with renal failure. Clin Pharmacol Ther 47: 5056.
  • Chang AM, Smith MJ, Galecki AT, Bloem CJ, Halter JB (2006). Impaired β-cell function in human aging: response to nicotinic acid-induced insulin resistance. J Clin Endocrinol Metab 91: 33033309.
  • Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB et al. (2001). A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7: 161171.
  • Cheung MC, Zhao X-Q, Chait A, Albers JJ, Brown G (2001). Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 21: 1201326.
  • Choplicki S, Swies J, Mogielnicki A, Buczko W, Bartus M, Lomnicka M et al. (2007). 1-methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. Br J Pharmacol 152: 230239.
  • Christie AW, McCormick DK, Emmison N, Kraemer FB, Alberti KG, Yeaman SJ (1996). Mechanism of anti-lipolytic action of acipimox in isolated rat adipocytes. Diabetologia 39: 4553.
  • Ciaccio M, Bivona G, Bellia C (2008). Therapeutical approach to plasma homocysteine and cardiovascular risk reduction. Ther Clin Risk Manag 4: 219224.
  • Ciampelli M, Leoni F, Lattanzi F, Guido M, Apa R, Lanzone A (2002). A pilot study of the long-term effects of acipimox in polycystic ovary syndrome. Hum Reprod 17: 647653.
  • Cipollone F, Fazia M, Iezzi A, Ciabattoni G, Pini B, Cuccurullo C et al. (2004). Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. Arterioscler Thromb Vasc Biol 24: 12591265.
  • Cohen B, Novick D, Rubinstein M (1996). Modulation of insulin activities by leptin. Science 274: 11851188.
  • Cordido F, Alvarez-Castro P, Isidro ML, Casanueva FF, Dieguez C (2003). Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients. Eur J Endocrinol 149: 117122.
  • Crepaldi G, Avogaro P, Descovich GC, Di Perri T, Postiglione A, Sirtori CR et al. (1988). Plasma lipid lowering activity of acipimox in patients with type 2 and type 4 hyperlipoproteinaemia. Atherosclerosis 70: 115121.
  • Culman J, Zhao Y, Gohlke P, Herdegen P (2007). PPAR gamma: a therapeutic target in ischaemic stroke. Trends Pharmacol Sci 28: 244249.
  • Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E (2006). Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically prediposed to type 2 diabetes. Am J Physiol Endocrinol Metab 292: E1775E1781
  • Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R et al. (2003). Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-γ (PPAR-γ), reduce ischaemia/reperfusion of the gut. Br J Pharmacol 140: 366376.
  • Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Britti D, Patel NS et al. (2004). Rosiglitazone, a ligand of the peroxisome proliferator-actvated receptor-γ, reduces acute pancreatitis induced by cerulein. Intensive Care Med 30: 951956.
  • DeSouza C, Keebler M, McNamara DB, Fonseca V (2002). Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs 62: 605616.
  • Despres J-P (2006). Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J 8: B4B12.
  • Devchand P, Keller H, Peters J, Vazquez M, Gonzalez F, Wahli W (1996). The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384: 3943.
  • Dhalla AK, Santikul M, Smith M, Wong M-Y, Shryock JC, Belardinelli L (2007). Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid. J Pharmacol Exp Ther 321: 327333.
  • Doggrell SA (2004). Inhibition of cardiac cytochrome P450: a new approach to cardiac ischaemia-reperfusion damage. Expert Opin Ther Targets 8: 491493.
  • Dullart RP, van Tol A (2001). Short-term acipimox decreases the ability of plasma from Type 2 diabetic patients and healthy subjects to stimulate cellular cholesterol efflux: a potentially adverse effect on reverse cholesterol transport. Diabet Med 18: 509513.
  • Dullart RP, Riemens SC, Meinardi JR, Wolffenbuttel BH, Sluiter WJ (2005). Plasma adiponectin is modestly decreased during 24-hour insulin infusion but not after inhibition of lipolysis by Acipimox. Scand J Clin Lab Invest 65: 523531.
  • Exton JH (1996). Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins. Annu Rev Pharmacol Toxicol 36: 481509.
  • Fu Y, Luo N, Lopes-Virella MF (2002). Upregulation of interleukin-8 expression by prostaglandin D2 metabolite 15-deoxy-delta12, 14 prostaglandin J2 (15d-PGJ2) in human THP-1 macrophages. Atherosclerosis 160: 1120.
  • Fucella LM, Goldaniga G, Lovisolo P, Maggi E, Musatti L, Mandelli V et al. (1980). Inhibition of lipolysis by nicotinic acid and by acipimox. Clin Pharmacol Ther 28: 790795.
  • Furnsinn C, Wilson TM, Brunmair B (2007). Peroxisome proliferator-activated receptor-δ, a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia 50: 817.
  • Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML (2009). Niacin inhibits vascular oxidative stress, redox–sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 202: 6875.
  • Gille A, Bodor ET, Ahmed K, Offermanns S (2008). Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol 48: 79106.
  • Gormsen LC, Jessen N, Gjedsted J, Gjedde S, Norrelund H, Lund S et al. (2007). Dose-response effects of free fatty acids on glucose and lipid metabolism during somatostatin blockade of growth hormone and insulin in humans. J Clin Endocrinol Metab 92: 18341842.
  • Green A, Bustillos DP, Misbin RI (1984). Beta-hydroxybutyrate increases the insulin sensitivity of adipocyte glucose transport at a post-receptor level. Diabetes 33: 10451050.
  • Green PJ, Vaiser T, Pennathur S, Kulstad JJ, Moore AB, Marcovina S et al. (2008). Combined statin and niacin therapy remodels the high density lipoprotein proteome. Circulation 118: 12591267.
  • Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendal DM, Fitz-Patrick D et al. (2002). Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med 162: 15681576.
  • Hadigan C, Liebau J, Torriani M, Andersen R, Grinspoon S (2006). Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia. J Clin Endocrinol Metab 91: 44384444.
  • Hall JM, McDonnell DP (2007). The molecular mechanisms underlying the proinflammatory action of thiazolidinediones in human macrophages. Mol Endocrinol 21: 17561768.
  • Hata AN, Breyer RM (2004). Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103: 147166.
  • van Herk T, Brussee J, van den Nieuwendijl AMCH, vander Klein PAM, Jzerman API, Stannek C et al. (2003). Pyrazole derivatives as potent agonists for the nicotinic acid receptor. J Med Chem 46: 39453951.
  • Hunninghake DB, Edwards KD, Sopko GS, Tosiello RL (1985). Controlled trial of acifran in type II hyperlipoproteinaemia. Clin Pharmacol Ther 38: 313317.
  • Kallai-Sanfacon MA, Cayen MN, Dubuc J, Greselin E, Dvornik D (1983). Effect of AY-25,712 and other lipid-lowering agents on liver catalase and liver carnitine acetyltransferase in rats. Proc Soc Exp Biol Med 173: 367371.
  • Kamanna VS, Kashyap ML (2007). Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol 100: S53S61.
  • Knowles HJ, Poole RT, Workman P, Harris AL (2006). Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem Pharmacol 71: 646656.
  • Kok P, Buijs M, Kok S, Van Ierssel I, Frolich M, Roelfsema F et al. (2004a). Acipmox enhances spontaneous growth hormone secretion in obese women. Am J Physiol Regul Integr Comp Physiol 286: R693R698.
  • Kok P, Kok SW, Buijs MM, Westenberg JJM, Roelfsema F, Frolich M et al. (2004b). Enhanced circadian ACTH release in obese premenopausal women: reversal by short-term acipimox treatment. Am J Physiol Endocrinol Metab 287: E848E856
  • Kostylina G, Simon D, Fey MF, Yousefi S, Simon HU (2008). Neutrophil apoptosis is mediated by nicotinic acid receptors (GP109A). Cell Death Differ 15: 134142.
  • LaRosa JC, Miller VT, Edwards KD, DeBovis MR, Stoy DB (1987). Acifran: a double-blind, randomized, placebo-controlled efficacy study in type IIa hyperlipoproteinemic patients. Artery 14: 338350.
  • Lamon-Fava S, Diffenderfer MR, Barrett PH, Buchsbaum A, Nyaku M, Horvath KV et al. (2008). Extended release niacin alters the metabolism of plasma apolipoprotein (Apo)-A1 and Apo-B-containing lipoproteins. Arterioscler Thromb Vasc Biol 28: 16721678.
  • Lee C-H, Kang K, Mehl IR, Nofsinger R, Alaynick WA, Chong L-W et al. (2006). Peroxisome proliferator-activated receptor δ promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage. Proc Natl Acad Sci USA 10: 24342439.
  • van Leeuwen M, Gijbels MJJ, Duijvestijn A, Smook M, van der Gaar MJ, Heeringa P et al. (2008). Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR−/− mice. Arterioscler Thromb Vasc Biol 28: 8489.
  • Lin W-W, Chen BC (1998). Distinct PKC isoforms mediate the activation of cPLA2 and adenylyl cyclase by phorbol ester in RAW264.7 macrophages. Br J Pharmacol 125: 16011609.
  • Mahboubi K, Witman-Jones T, Adamus JE, Letsinger JT, Whitehous D, Moorman AR et al. (2006). Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G-protein coupled receptors HM74A and HM74. Biochem Biophys Res Commun 340: 482490.
  • Maciejewski-Lenoir D, Richman JG, Hakak Y, Gaidarov I, Behan DP, Connolly DT (2006). Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol 126: 26372646.
  • McKenney J (2004). New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 164: 697705.
  • Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M et al. (2007). PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet 3: e64
  • Meuwese MC, Stroes ESG, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG et al. (2007). Serum myeloperoxidase levels are associated with the future coronary artery disease in apparently healthy individuals. J Am Coll Cardiol 50: 159165.
  • Meyers CD, Liu P, Kamanna VS, Kashyap ML (2007). Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush. Atherosclerosis 192: 25258.
  • Miwa Y, Takiuchi S, Kamide K, Yoshii M, Horio T, Tanaka C et al. (2004). Identification of lipocalin-type prostaglandin D synthase and its association with carotid atherosclerosis in Japanese hypertensive patients. Biochem Biophys Res Commun 322: 428433.
  • Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D et al. (2001). The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 7: 4147.
  • Morrow JD, Parsons WG, Roberts LJ (1989). Release of markedly increased quantities of prostaglandin D2 in vivo in humans following administration of nicotinic acid. Prostaglandins 38: 263274.
  • Morrow JD, Awad JA, Oates JA, Roberts LJ (1992). Identification of skin as a major site of prostaglandin D2 release follwoing oral administration of niacin in humans. J Invest Dermatol 98: 812815.
  • Muller G, Ertl J, Gerl M, Preibisch G (1997). Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem 272: 1058510593.
  • Napimoga MH, Viera SM, Dal-Secco D, Freitas A, Sonto FO, Mestringer FL et al. (2008). Peroxisome proliferator-activated receptor-γ ligand, 15-deoxy-Δ12–14 – Prostaglandin JZ, reduces neubrophil migration via a nitric oxide pathway. J Immunol 180: 609617.
  • Nesto RW (2005). Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 5: 379387.
  • Newby AC (2000). An overview of the vascular response to injury: a tribute to the late Russell Ross. Toxicol Lett 112113: 519529.
  • Nicholson AC (2004). Expression of CD36 in macrophages and atherosclerosis. The role of lipid regulation of PPARγ signaling. Trends Cardiovasc Med 14: 812.
  • Nissen SE, Wolski K (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 24572471.
  • O'Kane MJ, Trinick TR, Tynan MB, Trimble ER, Nicholls DP (1992). A comparison of acipmox and nicotinic acid in type b hyperlipidaemia. Br J Clin Pharmac 33: 451453.
  • Oda N, Imamura S, Fujita T, Uchida Y, Inagaki K, Kakizawa H et al. (2008). The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism 57: 268273.
  • Offermanns S (2006). The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol Sci 27: 384390.
  • Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL et al. (2001). A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98: 53065311.
  • Papaliodis D, Boucher W, Kemperaj D, Michaelian M, Wolfberg A, House M et al. (2008). Niacin-induced ‘flush’ involves release of PGD2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model. J Pharmacol Exp Ther 327: 665672.
  • Patti ME, Butte AJ, Crunkhorn S, Kusi K, Berria R, Kashyap S et al. (2003). Co-ordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 100: 84668471.
  • Paulsson J, Dadfar E, Held C, Jacobson SH, Lundahl J (2006). Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease. Atherosclerosis 192: 328334.
  • Paz-Filho G, Eposito K, Hurwitz BE, Sharma A, Dong C, Andreev VP et al. (2008). Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients. Am J Physiol Endocrinol Metab 295: E1401E1408. Oct 14 [Epub ahead of print]
  • Pike NB, Wise A (2004). Identification of a nicotinic acid receptor: is this the molecular target for the oldest lipid-lowering drug? Curr Opin Investig Drugs 5: 271275.
  • Plaisance EP, Mestek ML, Mahurin AJ, Taylor JK, Moncada-Jimenez J, Grandjean PW (2008). Postprandial triglyceride responses to aerobic exercise and extended-release niacin. Am J Clin Nutr 88: 3037.
  • Poldermans D, Dunkelgrun M, Schouten O, Hostalek U (2008). Niaspan-induced HDL elevation for optimising risk control (NEMO) study. Eur Surg Res 41: 313318.
  • Pontiroli A, Manzoni M, Malighetti M, Lanzi R (1996). Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obses subjects by acute pharmacological reduction of plasma free fatty acids. J Clin Endocrinol Metab 81: 39984001.
  • Potter K, Hankey GJ, Green DJ, Eikelboom J, Jamrosik K, Arnolda LF (2008). The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomised controlled trial and meta-analysis. BMC Cardiovasc Disord 8: 24.
  • Powell DJ, Turban S, Gray A, Hajducjh E, Hundal HS (2004). Intracellular ceramide synthesis and protein kinase Czeta activation play an essential role in palmitate-induced insulin resistance in rat L6 skeletal muscle cells. Biochem J 382: 619629.
  • Poynten AM, Gan SK, Kriketos AD, O'Sullivan A, Kelly JJ, Ellis BA et al. (2003). Nicotinic acid-induced insulin resistance is related to increasing circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism 52: 699704.
  • Psaty BM, Furberg CD (2007). The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med 357: 6769.
  • Ragiola L, Palaia T, Hall CE, Maesaka JK, Eguchi N, Urade Y (2005). Accelerated glucose intolerance, nephropathy and atherosclerosis in prostaglandin D2 synthase knock-out mice. J Biol Chem 280: 2994629955.
  • Rajakariar R, Hilliard M, Lawrence T, Trivedi S, Colville-Nash P, Bellingan G et al. (2007). Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyΔ12–14PGJ2. Proc Natl Acad Sci USA 104: 2097920984.
  • Rhee SG (2001). Regulation of phosphoinositide-specific phospholiase C. Annu Rev Biochem 70: 281312.
  • Richman JG, Kanemitsu-Parks M, Gaidarov I, Cameron JS, Griffin P, Zheng H et al. (2007). Nicotinic acid receptor agonists differentially activate downstream effect. J Biol Chem 282: 1802818036.
  • Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998). The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391: 7982.
  • Ricote M, Huang JT, Welch JS, Glass CK (1999). The peroxisome proliferator-activated receptor (PPAR-γ) as a regulator of monocyte/macrophage function. J Leukocyte Biol 66: 733739.
  • Rubic T, Trottmann M, Lorenz RL (2004). Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 67: 411419.
  • Sadig H, Pease JE, Saroe I (2007). Contrary prostaglandins: the opposing roles of PGD2 and its metabolites in leukocyte function. J Leukoc Biol 81: 372382.
  • Sanchez-Vera I, Bonet B, Viana M, Herrera E, Indart A (2002). Effect of acipimox on plasma lipids and glucose/insulin in pregnant rats. Int J Exp Diabetes Res 3: 233239.
  • Sauve AA (2008). NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther 324: 883893.
  • Scher JU, Pillinger MH (2005). 15d-PGJ2: the anti-inflammatory prostaglandin? Clin Immunol 114: 100109.
  • Schinkel AFL, Bax JJ, Valkema R, Elhendy A, van Domburg RT, Vourvouri EC et al. (2003). Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability. J Nucl Med 44: 877883.
  • Schubert K, Sheid M, Duronio V (2000). Ceramide inhibits protein kinase B/Akt signalling by promoting dephosphorylation of serine 473. J Biol Chem 275: 1333013335.
  • Shen HC, Ding F-X, Luell S, Forrest MJ, Carballo-Jane E, Wu KK et al. (2007). Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor. J Med Chem 50: 63036306.
  • Soga T, Kamohara M, Takasaki J, Matsumoto S, Saito T, Ohishi T et al. (2003). Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 303: 364369.
  • Spiegelman B (1998). PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507514.
  • Stoll G, Bendszus M (2006). Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 37: 19231932.
  • Stuyt PMJ, Kleinjans HAJ, Stalenhoef AFH (1998). Tolerability and effects of high doses acipimox as additional lipid-lowering therapy in familial hypercholesterolemia. Netherlands. J Med 53: 228233.
  • Taggart AKP, Kero J, Gan X, Cai T-Q, Cheng K, Ippolito M et al. (2005). (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem 280: 2664926652.
  • Takahashi S, Tanaka T, Sakai J (2007). New therapeutic target for metabolic syndrome: PPARδ. Endocr J 54: 347357.
  • Tang Y, Zhou L, Gunnet JW, Wines PG, Cryan EV, Demarest KT (2006). Enhancement of arachidonic acid signalling pathway by nicotinic acid receptor HM74A. Biochem Biophys Res Commun 345: 2937.
  • Taylor AJ, Sullenberger LE, Lee HJ, Grace KA (2004). Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110: 35123517.
  • Taylor AJ, Zhu D, Sullenberger LE, Lee HJ, Lee JK, Grace KA (2007). Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2. Vasc Health Risk Manag 3: 159164.
  • Teruel T, Hernandez R, Lorenzo M (2001). Ceramide mediates insulin resistance by tumor necrosis factor-α in brown adipocytes by maintaining Akt in an inactive dephosphorylated state. Diabetes 50: 25632571.
  • The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators (2006). Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368: 10961105.
  • Thoenes M, Oguchi A, Nagamia S, Vaccari CS, Hammoud R, Umpierrez GE et al. (2007). The effects of extended-release niacin on carotid intimal thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int J Clin Pract 61: 19421948.
  • Tunaru S, Lattig J, Kero J, Krause G, Offermanns S (2005). Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Mol Pharmacol 68: 12711280.
  • Vickers MH, Hofman PL, Gluckman PD, Lobie PE, Cutfield WS (2006). Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational age rat. Am J Physiol Endocrinol Metab 291: E1212E1219
  • Vittone F, Chait A, Morse JS, Fish B, Brown G, Zhao X-Q (2007). Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: a subgroup analysis of the HDL-atherosclerosis treatment study (HATS). J Clin Lipidol 1: 203210.
  • Vosper H, Patel L, Graham TL, Khoudoli GA, Hill A, Macphee CH et al. (2001). The peroxisome proliferators-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem 276: 4425844265.
  • Wang-Fisher Y-L, Han J, Guo W (2002). Acipimox stimulates leptin production from isolated rat adipocytes. J Endocrinol 174: 267272.
  • Watson PM, Commins SP, Beiler RJ, Hatcher HC, Gettys TW (2000). Differential regulation of leptin expression and function in A/J vs C57BL/6J mice during diet-induced obesity. Am J Physiol Endocrinol Metab 279: E356E365.
  • Watt MJ, Southgate RJ, Holmes AG, Febbraio MA (2004). Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator 1alpha in human skeletal muscle, but not lipid regulatory genes. J Mol Endocrinol 33: 533544.
  • Wise A, Foord JM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M et al. (2003). Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 278: 98699874.
  • Worm D, Vinten J, Vaag A, Henriksen JE, Beck-Nielsen H (2000). The nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in Type 2 diabetic patients. Eur J Endocrinol 143: 389395.
  • Zhang J, Fu M, Zhu X, Xiao Y, Mou Y, Zheng H et al. (2002). Peroxisome proliferator-activated receptor δ is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells. J Biol Chem 277: 1150511512.
  • Zhang J, Ge H, Wang CQ, Guo TB, He Q, Shao Q et al. (2007). Inhibitory effect of PPAR on the expression of EMMPRIN in macrophages and foam cells. Int J Cardiol 117: 373380.
  • Zhao SP, Yang J, Li J, Dong SZ, Wu ZH (2008). Effect of niacin on LXRalpha and PPARgamma expression in HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits. Int J Cardiol 124: 172178.